LEGISLATIVE BUDGET BOARD Austin, Texas FISCAL NOTE, 84TH LEGISLATIVE REGULAR SESSION April 16, 2015 TO: Honorable Charles Schwertner, Chair, Senate Committee on Health & Human Services FROM: Ursula Parks, Director, Legislative Budget Board IN RE:SB1462 by West (Relating to the prescription, administration, and possession of certain opioid antagonists for the treatment of suspected opioid overdoses.), Committee Report 1st House, Substituted No significant fiscal implication to the State is anticipated. The bill would add a new subchapter to the Health and Safety Code that would authorize the prescription, distribution, possession, and administration of opioid antagonists in certain circumstances. The Department of State Health Services and Health and Human Services Commission indicate costs associated with the bill could be absorbed within current resources. This analysis assumes the bill would not result in a significant increase in individuals seeking an opioid antagonist. This analysis assumes the provisions of the bill addressing felony sanctions for criminal offenses would not result in a significant impact on state correctional agencies. Local Government Impact No significant fiscal implication to units of local government is anticipated. Source Agencies:515 Board of Pharmacy, 405 Department of Public Safety, 529 Health and Human Services Commission, 537 State Health Services, Department of LBB Staff: UP, ADe, NB, WP, KVe, VJC, LR, ESi
LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 84TH LEGISLATIVE REGULAR SESSION
April 16, 2015
TO: Honorable Charles Schwertner, Chair, Senate Committee on Health & Human Services FROM: Ursula Parks, Director, Legislative Budget Board IN RE:SB1462 by West (Relating to the prescription, administration, and possession of certain opioid antagonists for the treatment of suspected opioid overdoses.), Committee Report 1st House, Substituted
TO: Honorable Charles Schwertner, Chair, Senate Committee on Health & Human Services
FROM: Ursula Parks, Director, Legislative Budget Board
IN RE: SB1462 by West (Relating to the prescription, administration, and possession of certain opioid antagonists for the treatment of suspected opioid overdoses.), Committee Report 1st House, Substituted
Honorable Charles Schwertner, Chair, Senate Committee on Health & Human Services
Honorable Charles Schwertner, Chair, Senate Committee on Health & Human Services
Ursula Parks, Director, Legislative Budget Board
Ursula Parks, Director, Legislative Budget Board
SB1462 by West (Relating to the prescription, administration, and possession of certain opioid antagonists for the treatment of suspected opioid overdoses.), Committee Report 1st House, Substituted
SB1462 by West (Relating to the prescription, administration, and possession of certain opioid antagonists for the treatment of suspected opioid overdoses.), Committee Report 1st House, Substituted
No significant fiscal implication to the State is anticipated.
No significant fiscal implication to the State is anticipated.
The bill would add a new subchapter to the Health and Safety Code that would authorize the prescription, distribution, possession, and administration of opioid antagonists in certain circumstances. The Department of State Health Services and Health and Human Services Commission indicate costs associated with the bill could be absorbed within current resources. This analysis assumes the bill would not result in a significant increase in individuals seeking an opioid antagonist. This analysis assumes the provisions of the bill addressing felony sanctions for criminal offenses would not result in a significant impact on state correctional agencies.
Local Government Impact
No significant fiscal implication to units of local government is anticipated.
Source Agencies: 515 Board of Pharmacy, 405 Department of Public Safety, 529 Health and Human Services Commission, 537 State Health Services, Department of
515 Board of Pharmacy, 405 Department of Public Safety, 529 Health and Human Services Commission, 537 State Health Services, Department of
LBB Staff: UP, ADe, NB, WP, KVe, VJC, LR, ESi
UP, ADe, NB, WP, KVe, VJC, LR, ESi